{"prompt": "['11 July 2019', 'ARGX-113-1704', 'ARGX-113', 'Protocol Version 3.0, Final', 'IgG levels up to 50%, while multiple dosing further lowered IgGs up to approximately 70%.', 'IgG levels returned to Baseline approximately 8 weeks following the last administration of', 'ARGX-113. IV administration of ARGX-113 at single doses up to 25 mg/kg and multiple', 'doses of 10 mg/kg and 25 mg/kg were safe and well tolerated.', 'Based on an optimal PD effect combined with minimal number of observed adverse events', '(AEs) (compared to the 25 mg/kg dose level), the dose of 10 mg/kg once weekly for 4 weeks', 'provided the most favorable risk-benefit profile and was therefore selected for further testing', 'in the Phase 2 trial. The outcome of the Phase 2 trial indicated the efficacy and safety of', '10 mg/kg in 4 weekly infusions in gMG patients.', 'ARGX-113-1602 was a randomized, double-blind, placebo-controlled, multicenter Phase 2', 'trial to evaluate the safety, efficacy, and PK of ARGX-113 for the treatment of autoimmune', 'MG patients with generalized muscle weakness. Eligible patients (24 in total) were', 'randomized at a 1:1 ratio to receive ARGX-113 (10 mg/kg) or placebo in 4 infusions', 'administered one week apart in addition to standard of care (SoC). The clinical effect of', 'ARGX-113 was explored in this trial using validated efficacy scales commonly used in MG', 'clinical research and practice: Myasthenia Gravis Activities of Daily Living (MG-ADL),', 'Quantitative Myasthenia Gravis (QMG), Myasthenia Gravis Composite (MGC), and 15 item', 'Quality of life scale for Myasthenia Gravis [revised version] (MG-QoL15r). The efficacy', 'data of the 4 scales consistently point in the same direction and show a rapid onset of action,', 'and a relevant and long-lasting clinical improvement over placebo. More specifically, on the', 'MG-ADL scale, 75% of the patients treated with ARGX-113 had a sustained clinically', 'relevant reduction in total MG-ADL scores (defined as a reduction of at least 2 points from', 'Baseline) for a period of at least 6 consecutive weeks (starting at the latest 1 week after last', 'infusion of the Investigational Medicinal Product [IMP]) versus 25% of patients on placebo', '(difference was found to be statistically significant). Furthermore, this clinical improvement', 'observed in all scales was in line with the observed PD data, namely a reduction of total IgG', 'and subtypes and a decreased level of AChR autoantibodies.', 'The proposed Phase 3 trial aims to establish the efficacy, safety and tolerability of ARGX-', '113 in class II-IVb gMG patients, and thereby validating the concept of autoantibody', 'reduction as a therapeutic treatment modality in this indication.', 'This trial will be performed in compliance with the protocol, International Council for', 'Harmonization, Good Clinical Practice (ICH GCP), Declaration of Helsinki, and other', 'applicable regulatory requirements.', '1.3.', 'Standard of Care and Rationale for Use of ARGX-113', 'Several drugs and medical procedures are routinely used in the management of gMG.', 'Acetylcholinesterase (AChE) inhibitors are frequently used in treatment of MG particularly', 'in the mild forms of the disease. These agents include drugs such as pyridostigmine,', 'argenx BVBA', 'Confidential', 'Page 45 of 110']['11 July 2019', 'ARGX-113-1704', 'ARGX-113', 'Protocol Version 3.0, Final', 'neostigmine, and edrophonium and their effectiveness varies widely. These drugs act by', 'inhibiting the enzyme AChE, which is responsible for the degradation of acetylcholine. This', 'prolongs the exposure of acetylcholine, which leads to an amelioration of the', 'signs/symptoms of MG. Acetylcholinesterase inhibitors provide a symptomatic treatment of', 'MG and do not act on the underlying pathogenic mechanism of the disease.', 'Acetylcholinesterase inhibitors however do not work in all patients with MG and usually', 'have a short duration of action requiring to be taken several times a day.', 'Corticosteroids and non-steroidal immunosuppressive drugs (NSIDs) are also used in the', 'treatment of MG. These drugs are frequently used in the more advanced stage of the disease.', 'Corticosteroids and NSIDs are typically characterized by delayed onset of effects. Because of', 'their multiple side effects, the lowest effective dose of corticosteroids is recommended for', 'long-term treatment that is often indicated for chronic conditions such as MG. Non-steroidal', 'immunosuppressive drugs are commonly used and include azathioprine, mycophenolate', 'mofetil, cyclosporine, and cyclophosphamide. The use of corticosteroids and NSIDs however', 'is associated with dose-dependent, frequent and often serious side effects whose management', 'requires to lower the dose and to use these drugs in various combinations to find the right', 'balance between efficacy and side effects (Gilhus and Verschuuren 2015; Gilhus 2016).', 'Apart from the SoC described above, new biologic agents such as rituximab and eculizumab', 'are also used in the treatment of specific cases of MG, such as resistant and refractory forms.', 'However, the use of these drugs is also associated with serious and sometimes life-', 'threatening side effects (Nowak, Dicapua et al. 2011; Howard, Utsugisawa et al. 2017).', 'Exacerbations of MG are treated using either therapeutic Plasma Exchange (PLEX),', 'immunoadsorption or IVIg. In the case of PLEX, typically one exchange, removing one to', 'two plasma volumes, is done every other day up to a total of four to six times, to improve', 'muscle strength or ameliorate a myasthenic crisis. Unfortunately, this treatment is invasive', 'and has frequent side effects such as hypotension, paresthesia, infections, and thrombotic', 'complications. IVIg is widely used for patients with exacerbating MG. The mechanism of', 'action of IVIg in MG is still unclear, and may include interference with autoantibodies,', 'B-cell modulation, saturation of FcRn and complement (Meriggioli and Sanders 2009; Liu,', 'Wang et al. 2010). In addition, the use of IVIg is burdensome for the patient.', 'These approaches however are not always available in all clinical centers since they require', 'specific facilities and instrumentation (Gilhus and Verschuuren 2015; Gilhus 2016).', 'Finally, in selected cases, surgical removal of the thymus gland is also used to ameliorate the', 'clinical manifestations of MG. However, thymectomy is not always effective in all patients', 'and is associated with surgery-specific risks (Drachman 1994; Gilhus and Verschuuren 2015;', 'Gilhus 2016; Wolfe, Kaminski et al. 2016).', 'Following administration of ARGX-113 (10 mg/kg) in 4 infusions administered one week', 'apart in addition to SoC in patients with autoimmune MG with generalized muscle weakness', 'argenx BVBA', 'Confidential', 'Page 46 of 110']\n\n###\n\n", "completion": "END"}